Loading stock…

Insulet Corporation (PODD) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Insulet Corporation

PODDMarket cap $9.34BPrice $134.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes the Omnipod, a tubeless insulin pump that sticks to your skin and delivers doses automatically, no needles, no tubing. Over 400,000 people with diabetes now wear one, ditching daily injections for good.

In Bastion Portfolios?

52W Return-58%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+28%10

Revenue Forecast

Rev CAGR (1y)+22%8

Rev CAGR (3y)+16%8

Rev CAGR (5y)+13%8

Earnings Forecast

EPS Growth Y+1+13%7

EPS Growth Y+2+19%8

EPS Growth Y+3+21%8

Quality

Margins

EBIT Margin17%7

Net Income Margin12%6

Free Cash Flow Margin10%6

Debt

Net Debt/EBITDA0.76

Efficiency

ROE26%9

ROA11%9

Earnings Stability88

GEAR+VERY STRONG89

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)145

P/BV6.62

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd165

Yield

Free Cash Flow Yield3.1%5

Dividend Yieldna–

Momentum

Short term

1 month return-9%3

3 month return-17%2

YTD return-53%1

Mid term

Price vs 52wHigh38%1

1 year return-57%1

Long term

3 year return-7%2

5 year return-54%1

Risk Shield

Price Risk

Beta0.39

Volatility46%3

Free Cash Flow

Free Cash Flow Margin10%6

Free Cash Flow Yield3.1%5

Quality

ROCE21%9

Earnings Stability88

Net Debt/EBITDA0.76

02Growth

Is it actually growing, and how fast?

PODDInsulet

Revenue FY25$2.1B

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+28%10

Revenue, next 1Y+22%8

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+13%7

EPS growth, FY27E+19%8

EPS growth, FY28E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 28%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 19%/yr vs revenue 16%/yr).

WATCH

Revenue grew 28%/yr over the last 3 years; forecasts see it cooling to 16%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK3 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-17%2

YTD return-53%1

MID & LONG-TERM▾SCORE

% of 52-week high38%1

1-year return-57%1

3-year return-7%2

5-year return-54%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.4% over three years and -54% over five), behind 80% of the market.

It's down 57% over the past year, now 62% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-9%), over three months (-17%) and so far this year (-53%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Insulet. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PODDInsulet

Revenue FY25$2.1B

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+28%10

Revenue, next 1Y+22%8

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+13%7

EPS growth, FY27E+19%8

EPS growth, FY28E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 28%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 19%/yr vs revenue 16%/yr).

WATCH

Revenue grew 28%/yr over the last 3 years; forecasts see it cooling to 16%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK3 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-17%2

YTD return-53%1

MID & LONG-TERM▾SCORE

% of 52-week high38%1

1-year return-57%1

3-year return-7%2

5-year return-54%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.4% over three years and -54% over five), behind 80% of the market.

It's down 57% over the past year, now 62% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-9%), over three months (-17%) and so far this year (-53%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Insulet. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community